Eliem Therapeutics Inc (ELYM)
10.16
+1.76
(+21.04%)
USD |
NASDAQ |
May 03, 16:00
10.14
-0.02
(-0.15%)
After-Hours: 20:00
Eliem Therapeutics Cash from Operations (Quarterly): -0.947M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.947M |
| September 30, 2023 | 3.49M |
| June 30, 2023 | -7.965M |
| March 31, 2023 | -15.18M |
| December 31, 2022 | -8.449M |
| September 30, 2022 | -4.175M |
| June 30, 2022 | -13.97M |
| March 31, 2022 | -10.78M |
| Date | Value |
|---|---|
| December 31, 2021 | -7.884M |
| September 30, 2021 | -12.97M |
| June 30, 2021 | -8.481M |
| March 31, 2021 | -6.74M |
| December 31, 2020 | -5.624M |
| September 30, 2020 | -2.381M |
| June 30, 2020 | -3.768M |
| March 31, 2020 | -2.325M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-15.18M
Minimum
Mar 2023
3.49M
Maximum
Sep 2023
-6.759M
Average
-7.312M
Median
Cash from Operations (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | -18.97M |
| Candel Therapeutics Inc | -7.422M |
| Cyclacel Pharmaceuticals Inc | -3.91M |
| Lipocine Inc | -2.022M |
| GlycoMimetics Inc | -7.615M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 36.75M |
| Cash from Financing (Quarterly) | 0.288M |
| Free Cash Flow | -20.60M |
| Free Cash Flow Per Share (Quarterly) | -0.0344 |
| Free Cash Flow Yield | -7.52% |